NYSE · AVTRHealthcareLab Analytical Instruments

Avantor financials

$15.24−0.33%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
Revenue$6.55B$6.78B$6.97B$7.51B$7.39B$6.39B$6.04B
Gross profit$2.14B$2.28B$2.36B$2.60B$2.50B$2.08B$1.92B
Gross margin32.7%33.6%33.9%34.6%33.9%32.5%31.8%
Operating income-$241.1M$638.2M$696.4M$1.13B$972.2M$706.8M$551.8M
Net income-$530.2M$711.5M$321.1M$662.3M$508.0M$52.0M-$335.1M
Net margin−8.1%10.5%4.6%8.8%6.9%0.8%−5.5%
Diluted EPS$-0.78$1.04$0.47$1.01$0.85$0.09$-0.84
EBITDA$954.1M$1.04B$1.26B$1.54B$1.35B$1.10B$950.7M
Operating cash flow$623.8M$840.8M$870.0M$843.6M$953.6M$929.8M$354.0M
Free cash flow$495.0M$692.0M$723.6M$710.2M$842.5M$868.2M$302.4M
Diluted shares680.6M681.9M678.4M679.4M599.6M583.4M401.2M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$365.4M$261.9M$262.9M$372.9M$301.7M$286.6M
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$3.99B$4.10B$5.59B$6.34B$7.07B$4.94B
Total assets$11.79B$12.11B$12.97B$13.46B$13.90B$9.91B
Total liabilities$6.23B$6.16B$7.72B$8.61B$9.70B$7.23B
Shareholders' equity$5.57B$5.96B$5.25B$4.86B$4.20B$2.67B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology